Working languages: English to Chinese
Chinese to English |
| Shaunna
Also a biomedical scientist
United States Local time: 18:19 EST (GMT-5)
Native in: English  , Chinese | | |
Quality medical translation/interpretation | Freelancer,  Verified site user | | Translation, Interpreting, Voiceover (dubbing), Subtitling | | Specializes in: | | Medical: Pharmaceuticals | Medical: Health Care | | Medical (general) | Biology (-tech,-chem,micro-) | | Medical: Cardiology | Medical: Instruments | | Genetics | Science (general) |
| Also works in: | | General / Conversation / Greetings / Letters | Nutrition | | Poetry & Literature | Social Science, Sociology, Ethics, etc. | | Sports / Fitness / Recreation | Surveying | | Tourism & Travel | Business/Commerce (general) | | Cinema, Film, TV, Drama | Environment & Ecology | | Finance (general) | Mechanics / Mech Engineering | | Manufacturing | Chemistry; Chem Sci/Eng | | Agriculture | Automation & Robotics | | Automotive / Cars & Trucks | Certificates, Diplomas, Licenses, CVs | | Construction / Civil Engineering | Engineering (general) | | Food & Dairy | Furniture / Household Appliances | | Livestock / Animal Husbandry | Medical: Dentistry |
More Less | | Questions answered: 219, Questions asked: 0 Easy / 79 PRO, PRO-level points: 464 | 9 projects entered  2 positive feedback from outsourcers | Project Details | Project Summary | Corroboration |
Translation
Volume: 7 hours
Completed: Dec 2007
Languages:
Chinese to English | Health Insurance Claim Items CN-EN
Ongoing project CN-EN for insurance handling. Medical expense receipts and documents, medical charts, hospital records, prescriptions. Averagely 7 hours per week.
Medical: Health Care, Medical (general), Medical: Health Care | No comment. |
Translation
Volume: 14293 chars
Completed: May 2007
Languages:
Chinese to English | Drug registration application
14,293 Char Drug Registration document CN>EN. Stability, Safety and Efficacy, Pharmacological Studies, Toxicity studies.
Medical: Pharmaceuticals | No comment. |
Translation
Volume: 375 chars
Completed: Apr 2007
Languages:
Chinese to English | Pharmaceutical patent translation
Pharmaceutical patent application, Claims
Chemistry; Chem Sci/Eng | No comment. |
Translation
Volume: 24000 chars
Completed: Apr 2007
Languages:
English to Chinese | Material Safety Data Sheet
24,000 words MSDS EN-CN. SDLX.
Chemistry; Chem Sci/Eng, Medical (general) | No comment. |
Translation
Volume: 10990 words
Completed: Mar 2007
Languages:
English to Chinese | 10,990 words consent forms for clinical trials
Clinical trials for pharmaceutical company, patient information sheets and consent forms
Medical: Pharmaceuticals | No comment. |
Translation
Volume: 9600 chars
Completed: Mar 2007
Languages:
Chinese to English | Company surveys
General / Conversation / Greetings / Letters | positive
Denyce Seow: Good team player, responsible and independent |
Translation
Volume: 4391 words
Completed: Feb 2007
Languages:
English to Chinese | 15 pages translation of consent forms for clinical trial
Medical: Pharmaceuticals | No comment. |
Editing/proofreading
Volume: 2056 chars
Completed: Feb 2007
Languages:
Chinese to English | 12 pages patient questionnaires
Medical: Health Care | positive
peiling: Dedicated and thorough editing. Highly recommended. |
Translation
Volume: 0 hours
Languages:
English to Chinese | Chemical safety
Chemical safety and emergency treatment; On-going project. 1 hour per week.
Medical (general), Chemistry; Chem Sci/Eng | No comment. |
More Less | Sample translations submitted: 6Chinese to English: 药物专利－ Pharmaceutical patent
Detailed field: Patents | Source text - Chinese
权利要求书
1. 一种XXXX晶型，其特征在于，使用Cu－Ka辐射，以2θ角度和晶面间距（d值）表示的X－射线粉末衍射在约9.4 (9.4)、16.5 (5.4)、18.2 (4.9)、19.0 (4.7)、19.7 (4.5) 有特征峰。
2. 一种制备XXXX药物制剂的药物活性物质，由普瑞巴林组成，其中含有权利要求1的XXXX晶型在50％以上。
3. 权利要求2的药物活性物质，其中含权利要求1的XXXX晶型在85％以上。
4. 含有权利要求1的XXXX晶型的药物组合物，其特征在于，它含有生理有效剂量的权利要求1所述的XXXX晶型和适宜的药物赋型剂。
5. 权利要求4所述的药物组合物，其中所述的药物组合物是片剂、散剂、颗粒剂和胶囊剂量形式的固体药物制剂。
6. 权利要求1的XXXX晶体的制备方法，包括下述步骤：
（1）将XXXX用1～100倍醇水混合溶剂微热溶解；
（2）醇水混合溶剂中醇水的体积比为0.1～100：1；
（3）趁热过滤，滤液冷却析晶；
（4）过滤，25~90۫C真空干燥。
7. 根据权利要求6所述的制备方法，其特征在于，步骤（1）所述的醇选自下述醇类中的一种或多种：乙醇、丙醇、异丙醇、丁醇。
| Translation - English
CLAIMS
What is claimed is:
1. A XXXX crystalline form, which is characterized by an x-ray powder diffraction pattern, recorded with Cu-Ka radiation, that shows characteristic peaks, expressed in terms of angle 2θ and interplanar distance (d), at approximately 9.4 (9.4), 16.5 (5.4), 18.2 (4.9), 19.0 (4.7), and 19.7 (4.5).
2. A pharmaceutical active substance used for formulating XXXX pharmaceutical preparations, composed of XXXX hat iand in which the proportion of the XXXX crystalline form of Claim 1 is >50%.
3. The pharmaceutical active substance according to Claim 2, wherein the proportion of XXXX crystalline form of Claim 1 is >85%.
4. A pharmaceutical composition containing the XXXX crystalline form of Claim 1, characterized by containing biological effective dose of the XXXX crystalline form of Claim 1 and an appropriate pharmaceutical excipient.
5. The pharmaceutical composition according to Claim 4, wherein the pharmaceutical composition is in a solid dosage form such as pills, powder, granules, or capsules.
6. The preparation process of the XXXX crystalline form of Claim 1, including following steps:
(1) Add XXXX to 1~100-fold alcohol-water mixed solvent and heat gently to dissolve;
(2) The volume ratio of alcohol:water in the alcohol-water mixed solvent is 0.1~100:1;
(3) Filter while hot, and cool the filtrate down to allow crystallization;
(4) Filter, and vacuum dry at 25~90۫C.
7. The preparation process as described in Claim 6, the characteristic of which is that the alcohol used in step (1) is selected from one or more of the following: ethanol, n-propyl alcohol, isopropyl alcohol, and butyl alcohol.
| English to Chinese: Material safety data sheet- 化学物质安全性资料表
Detailed field: Chemistry; Chem Sci/Eng | Source text - English
10. Stability and reactivity
Stability: Stable under normal conditions.
Incompatibility: None with common materials and contaminants with which the material may reasonably come into contact.
Hazardous decomposition products: Carbon oxides, metal oxides.
Hazardous Polymerization: Hazardous polymerization does not occur.
11. Toxicological information
Effects of Exposure
General advice:
Contains: Colorant. The toxicological properties of this material have not been fully evaluated. The pigment in this product is imbedded in a tough plastic matrix which minimizes the likelihood of exposure to the pigment.
Contains: Carbon black. In 1996 the International Agency for Research on Cancer (IARC) reevaluated carbon black as a Group 2B carcinogen (possible human carcinogen), based upon the development of lung tumors in rats receiving chronic inhalation exposures to free carbon black. The effects were observed only in animals exposed to high concentrations of carbon black at levels that induce particle overload of the lung. Studies performed in animal models other than rats have not demonstrated an association between carbon black and lung tumors. Moreover, a two-year cancer bioassay using a typical toner preparation containing carbon black demonstrated no association between toner exposure and tumor development in rats. Epidemiology studies of workers in the carbon black producing industries of North America and Western Europe do not demonstrate an association between carbon black and cancer, even in high exposure occupational settings. In addition, in its reevaluation of carbon black, IARC concluded that "there is inadequate evidence in humans for the carcinogenicity of carbon black." Chronic overexposure to many dusts, including carbon black dust, may result in respiratory tract irritation and slight changes in lung function. Collectively, the available animal data and human epidemiology studies suggest that carbon black, as contained in this product, does not present a cancer risk to the end user if the handling and personal protective measures contained within this Material Safety Data Sheet are understood and followed.
Inhalation: Expected to be a low hazard for recommended handling.
Eyes: No specific hazard known. May cause transient irritation.
Skin: Expected to be a low hazard for recommended handling.
Ingestion: Expected to be a low ingestion hazard.
| Translation - Chinese
10. 穩定性與反應性
穩定性：在通常狀況下穩定。
不相容性：與常見物質及本物質難免接觸的其他雜物無不相容。
有害分解產物：碳氧化合物、金屬氧化物。
有害聚合：不會發生有害聚合。
11. 毒理資訊
暴露效應
一般性建議：
含有：色料。此物質的毒理學特性尚無完全評估。此產品中的顔料嵌于緊密的塑膠基材中，以此將色素污染的可能性降到最低。
含有：碳黑。國際癌病研究機構（IARC）於1996年根據慢性吸入性暴露於游離碳黑的大鼠肺腫瘤的生成情況，對碳黑作爲2B類致癌物（可能對人類致癌物質）的判定進行了重新評估。試驗顯示此效應僅發生於暴露在引起了肺部顆粒過負載的高濃度碳黑之下的動物。在其他動物模型中進行的試驗未顯示有碳黑與肺腫瘤之間的關聯。而且，一項爲期兩年的癌症生化分析研究了典型的含碳黑的墨粉配置程序對大鼠的影響，結果顯示暴露於調色劑並不會導致大鼠的腫瘤發生。對北美和西歐碳黑生産工業的工人的流行病學調查顯示，即使在暴露性高的職業環境中，碳黑也不會引發癌症。另外，在其對碳黑的重新評估中，IARC得出“碳黑作爲人類致癌物的依據不足”的結論。對很多粉塵的長期過量暴露，包括碳黑，都可能導致呼吸道刺激和肺功能的輕微變化。綜合上述，現有的動物試驗數據及人類流行病學研究都表明，如果終端用戶明瞭並依從本物質安全資料表中所述的存取及個人保護措施，則本產品所包含的碳黑不會帶給用戶癌症風險。
吸入：若依建議方式存取，當屬低度危害物質。
眼睛：無已知危害。可能引起暫時性刺激。
皮膚：若依建議方式存取，當屬低度危害物質。
食入：食入危害當屬低度。
| Chinese to English: 药物申报－ Drug registration application
Detailed field: Medical: Pharmaceuticals | Source text - Chinese
3.2药代动力学研究
建立了LC/MS/MS方法对样品中XXXX浓度进行分析，该方法用于分析50 μL血浆的生物样品中XXXX浓度范围为6.86–5000 ng/mL，并对本品的吸收、分布、代谢和排泄进行了测定。
在大鼠、小鼠和犬进行的药动学研究结果表明，胃肠道吸收较快。XXXX在不同动物的口服生物利用度有一定差异，其中大鼠的口服生物利用度为40–54%（p.o.剂量为30 mg/kg、i.v.剂量为10 mg/kg）、小鼠的口服生物利用度为55–68%（p.o.剂量为100 mg/kg、i.v.剂量为30 mg/kg）。犬的口服生物利用度表现出雌雄差异，其中雄性犬为44.1%（p.o.剂量为10 mg/kg、i.v.剂量为3 mg/kg）、雌性犬为4.40%（p.o.剂量为10 mg/kg、i.v.剂量为3 mg/kg）。
口服给药剂量与XXXX在雌雄大鼠体内达到的峰浓度（Cmax）呈正相关（r雄 = 0.999、r雌 = 0.912），与总暴露水平AUC也呈正相关（r雄 = 0.988、r雌 = 0.977）；口服给药剂量与XXXX在雌雄小鼠体内达到的峰浓度（Cmax）呈正相关（r雄 = 0.962、r雌 = 0.946），与总暴露水平AUC也呈正相关（r雄 = 0.997、r雌 = 0.998）；口服给药剂量与XXXX在雌雄犬体内达到的峰浓度（Cmax）呈正相关（r雄 = 0.988、r雌 = 0.990），与总暴露水平AUC也呈正相关（r雄 = 0.988、r雌 = 0.991）。XXXX在多数组织中的峰浓度（Cmax）略低于血浆中的峰浓度，在组织中的达峰时间（多数为20 min）晚于在血浆中的达峰时间（5 min）。口服给药（100 mg/kg）后，雌性大鼠肝脏对XXXX的暴露水平（AUC雌，肝 = 75.1 L/h/kg）略高于雄性大鼠肝脏（AUC雄，肝 =32.2 L/h/kg）。XXXX口服给药后，其在胃和小肠中的浓度很高。
静脉注射给药后，XXXX在大鼠、小鼠、犬体内的稳态表观分布体积（Vss）分别为2.22–2.61 L/kg（大鼠）、1.46–1.55 L/kg（小鼠）、0.90–4.22 L/kg（犬）；另一方面，XXXX在大鼠、小鼠、犬体内的总清除率（CL）分别为2.34–4.11 L/h/kg（大鼠）、1.74–2.16 L/h/kg（小鼠）、0.91–1.81 L/h/kg（犬）。静脉注射给药后，XXXX在大鼠、小鼠、犬体内的消除半衰期（T1/2）为0.5–2.9 h。
大鼠经口服灌胃给药100 mg/kg后，应用LC/MS分析技术从大鼠尿、粪、胆汁及血浆样品中检测原型药物和代谢产物。结果表明：口服给药后，XXXX原型药物从大鼠尿（0–72 h）、粪（0–72 h）、胆汁（0–48 h）的排泄均很少，主要以代谢物形式排泄，样品中检出代谢物M、M2、M3、M4。同时XXXX在粪中的排泄很少。这些代谢物因给药XXXX而产生，并随时间而从体内消除。推测的这些代谢物的化学结构得知，XXXX的主要代谢产物包括在CYP酶作用下的羟基化代谢产物M1及其进一步氧化（羧基化）代谢产物M2，同时还有在二相代谢酶（SULT和UGT）作用下的硫酸酯化代谢产物M3和葡萄糖醛酸化代谢产物M4。在以上大鼠生物样品中未发现M1和M2的二相（硫酸酯化和葡萄糖醛酸化）代谢产物。
采用超滤法测定XXXX与大鼠和犬血浆蛋白的结合率。结果显示： XXXX与本研究所用的超滤器的非特异性结合很弱（< 1%），可以忽略不计。XXXX与大鼠和犬血浆的蛋白结合率均比较低（< 10%），说明药物在血浆中主要以游离形式存在。
| Translation - English
3.2 Pharmacokinetics Studies
A LCM/MS method was established to analyze the XXXX concentration in the specimens. This method was used to detect 6.86–5000 ng/mL XXXX in 50 μL plasma, and to examine the absorption, distribution, metabolism, and excretion of XXXX.
Pharmacokinetical studies in rats, mice and dogs showed that XXXX was relatively rapidly absorbed through gastrointestinal tract. The oral biological availability of XXXX varied in different species. The oral biological availability for rats was 40-54% (p.o. dose 30 mg/kg, i.v. dose 10 mg/kg), and 55-68% (p.o. dose 100 mg/kg, i.v. dose 30 mg/kg) for mice. The oral biological availability of XXXX in dogs differed with gender, at 44.1% (p.o. dose 10 mg/kg, i.v. dose 3 mg/kg) for male dogs and 4.40% (p.o. dose 10 mg/kg, i.v. dose 3 mg/kg) for female dogs.
The oral dose of XXXX positively correlated with the peak XXXX concentration (Cmax) in vivo (r[male]=0.999, r[female]=0.912) as well as the total exposure level (AUC) (r[male]=0.988, r[female]=0.977) of XXXX in male and female rats; The oral dose of XXXX positively correlated with the peak XXXX concentration (Cmax) in vivo (r[male]=0.962, r[female]=0.946) as well as the total exposure level (AUC) (r[male]=0.997, r[female]=0.998) of XXXX in male and female mice; The oral dose of XXXX positively correlated with the peak XXXX concentration (Cmax) in vivo (r[male]=0.988, r[female]=0.990) as well as the total exposure level (AUC) (r[male]=0.988, r[female]=0.991) of XXXX in male and female dogs. The peak XXXX concentration (Cmax) in most tissues was slightly lower than that in the plasma, and the time to peak in the tissues (around 20 min) was longer than that in plasma (5 min). The hepatic exposure of female rats (AUC[liver]=75.1 L/h/kg) was slightly higher than that of male rats (AUC[liver]=32.2 L/h/kg) following oral administration of XXXX (100 mg/kg). The concentration of XXXX was very high in the stomach and the intestine following oral administration of XXXX.
After intravenous (i.v.) administration, the apparent volumes of distribution at steady state (Vss) were 2.22-2.61 L/kg, 1.46-1.55 L/kg, and 0.90-4.22 L/kg for rats, mice, and dogs respectively; On the other hand, the systemic clearance rates (CL) were 2.34-4.11, 1.74-2.16, and 0.91-1.81 L/h/kg for rats, mice, and dogs respectively. The elimination half-times were 0.5-2.9 h in rats, mice and dogs following i.v. administration of XXXX.
The parent compound and its metabolites were detected using the LC/MS assay following gavage administration of 100 mg/kg XXXX. The results showed that: Following oral administration of XXXX, only limited amount of the parent compound was excreted from urine (0-72 h), feces (0-72 h) and bile (0-48h). The drug was primarily excreted as metabolites. Metabolites M, M2, M3, and M4 were detected in the specimens. Meanwhile XXXX was rarely excreted through feces. These metabolites appeared with the administration of XXXX and cleared with time. Conjectured from the chemical structures of these metabolites, the main metabolites of XXXX should include CYP-catalyzed hydroxylated metabolite M1 and its further oxylated (carboxylation) metabolite M2, and dimorphic enzyme (SULT and UGT)-catalyzed sulfo-esterification metabolite M3 and glucuronidized metabolite M4. No dimorphic (sulfo-esterification and glucuronidization) metabolite of M1 and M2 was found in the biological specimens above from rats.
Ultrafiltration technique was used to test the binding rate of XXXX to rat and dog plasma proteins. Results: The non-specific binding of XXXX to the ultrafilter used in this study was very weak (<1%) and can be ignored. The binding rates of XXXX to both rat and dog plasma proteins were low (<10%), indicating a primarily unbound form of the drug in the plasma.
| Chinese to English: 病历－medical chart
Detailed field: Medical: Health Care | Source text - Chinese
Handwritten Chinese.
主诉： 双髋，膝不适6个月。
现病史：缘于04年9月，自觉双髋疼痛，劳累后加重。即到$$$$医院拍X光片检查，未见异常。因病情逐渐加重，左侧较重。又于05.2.7到$$$$做MRI检查。诊断双侧股骨头坏死。给予止痛药口服（名，量不详）约半年，未行其他方法治疗。经人介绍05.8.8来我院。经问诊以双侧股骨头坏死入院治疗。05.8.18症状好转出院， 05.12.21至06.5.8三次入院复查。2周前因左髋部疼痛，劳累后疼痛加重，于今日第4次以双侧股骨头坏死，双膝关节坏死由门诊收入院治疗。整个病程无潮热，盗汗，皮肤无瘘道，现双髋，膝不适，功能正常，睡眠，饮食及二便正常。
既往史：该患9岁时患哮喘间断治疗，服用激素药至05年9月。现病情稳定，否认肝炎，结核等传染病史。
体格检查：
体温（T）： 36.0‘C 脉搏（P） 64 次/分钟 呼吸（R） 18次/分
血压（BP) 120/75 mmHg 神志： 清楚 面色：润泽 发育：正常 营养：中等
体型：适中 步态：跛行 语言：流利 舌体：适中 舌质：暗 舌苔：薄
脉象：沉涩
皮肤黏膜：无出血点及黄染 浅表淋巴结：不肿大
头面部：头颅大小正常，无畸形，两眼瞳孔等大等圆，对光反射存在.
颈顶：颈软，气管适中，甲状腺不肿大
胸部：对称，无畸形，心肺无异常 心律 64 次/分 各瓣膜未闻及杂音
腹部：平坦，柔软，肝脾未触及。肠鸣音正常，肾区无压痛及扣击痛。
| Translation - English
PRIMARY COMPLAINT: Discomfort in bilateral hips and knees for 6 months.
HISTORY OF PRESENT ILLNESS: Started from September 2004, the patient felt pain in bilateral hips, which was aggravated when he was tired. The patient went to $$$$ Hospital for an X-Ray test, and no abnormity was discovered. Due to the gradual aggravation of the symptoms, he went to $$$$ Hospital for MRI test on 2/7/2005, and was diagnosed with bilateral femoral head necrosis. He was given oral pain-relieve medication (no detail on names and doses) for around half a year. No other treatment was implemented. The patient came to our hospital through referral on 8/8/2005. Following interrogation, he was admitted with bilateral femoral head necrosis. The patient was discharged on 8/18/2005 after his symptoms had alleviated. Between 12/21/2005 and 5/8/2006, the patient returned to our hospital three times for follow-up evaluations. During the past two weeks, the patient suffered pain in left hip which aggravated when he got tired, and was admitted today, for the 4th time, for further treatments from the outpatient department with bilateral femoral head necrosis and osteonecrosis of knees. Throughout the disease course there was no hectic fever or night sweat, nor formation of skin fistula. Presently there is discomfort in bilateral hips and knees, while the functions of which are normal. Sleeping, appetite, and excrements are normal.
PAST MEDICAL HISTORY: The patient has been suffering from asthma since he was 9 years old, and has been given intermittent treatments. He had been taking steroid medications until September 2005. Now his condition is stable. He denied any infectious disease history of hepatitis or TB.
PHYSICAL EXAMINATION
TEMP(T): 36.0۫C PULSE(P): 64/min RESP(R): 18/min BP: 120/75 mmHg
CONSCIOUSNESS: clear COMPLEXION: healthy reddish
DEVELOPMENT: normal NUTRITION: average BODY BUILD: moderate
WALKING: lame SPEECH: fluent TONGUE: moderate
TONGUE CHARACTERISTICS: dark TONGUE COATING: thin
PULSE CONDITION: slow and damp
SKIN AND MUCOSA: No petechia or jaundice
SUPERFICIAL LYMPH NODES: No swelling
HEAD AND FACE: Skull is of normal size, no malformation. Pupils are of same size and roundness, and reflex to light exists.
NECK: Neck is flexible. Trachea lies in the middle. Thyroid gland is not swollen.
CHEST: Symmetric. No malformation. No abnormity of heart and lungs. Heart rate 64/min. No murmur heard from valves.
ABDOMEN: Flat, soft. Liver and spleen not palpable. Bowel sounds normal. No pain in kidney area upon pressure or percussion. | English to Chinese: Equipment manual- 设备说明书
Detailed field: Engineering: Industrial | Source text - English
Preparatory treatment
The subsurface must be dry (wood moisture max. 14 %) and free from greasy impurities. Final smoothness 120 grain.
Fabrication Rollers: Typical rollers are supplied by companies such as Bürkle, Hymen, Superficci and Ceflar.
The rubber coating must be made from polyurethane with a shore hardness of 25. Resistant to alkali (light), acids (light) and various solvents such as aromatic free solvent naphtha, alcohols, plant based oils, etc. (see manufacturer’s instructions).
The wood is pre-warmed to 40 5 °C using IR lamps (pore opening).
Order quantity is to be calculated. Experimental value: depending on absorbency of the wood 20-30 g/m².
Please see the enclosed diagram of a rolling mill train for parquet flooring (oil treated).
Drying
The drying process is dependent upon the surrounding environment (20-23 °C, 55-65 % rel. air humidity). A nozzle dryer is ideal for the temperatures indicated here. The drying time for the above guidelines is 5-7 min. depending on the amount of oil applied.
The parquet flooring can then be stacked back to front side.
Care
Wet clean with Floorservice parquet cleaner. (please follow care instructions!)
Should the surface show signs of wear, the floor should be thoroughly cleaned and then treated with Floorservice care oil. It is important that the surface is retreated before it has been worn down to the wood otherwise it will need to be sanded and built up again.
Usage/yield
Usage 20-30 ml/m²,
Cleaning the tools
Before drying out, use commercially available white spirit.
Storage
Store in cool and dry conditions. Close container properly.
Container
10 l / 30 l sheet metal container
Safety information
Soak or dry cloths impregnated with Profiline hardwax oil on non-flammable surfaces (danger of spontaneous ignition!). Then dispose of with household waste. Natural products also do not belong in the hands of children.
Due to the natural raw materials that are used, a distinctly typical odour may occur!
Disposal
Containers should be swept clean and then disposed of at a recycling centre. Dried-on product remnants can be disposed of with household waste.
| Translation - Chinese
预备处理
亚表面层必须是干燥的(最大木材干燥度为14%)且无油污。最终的平滑度为120纹。
制作过程
辊轴：典型的辊轴是由Bürkle， Hymen， Superficci，以及Ceflar这些公司提供的。
橡胶涂层需由肖氏硬度为25的聚氨酯制成，能抵御（弱）碱、（弱）酸、以及各种溶剂如无芳烃溶剂石脑油、酒精类、及植物性油剂等。(参见制造商的说明)
木材由红外灯预热到40 5 ۫۫C(打开毛细孔)。
订货量由计算决定。实验值为20-30 g/m²，依木材的吸收率不同而异。
请参见附带的用于镶木地板（油处理）的辊轧机示意图。
干燥
干燥过程取决于周围的环境(20-23 ۫۫C， 55-65%相对空气湿度)。在此温度范围内使用喷嘴式干燥机就很合适。根据所涂油量的不同，需5－7分钟干燥时间以达到上述指定的范围。
完成后的镶木地板可以堆回前端。
维护
使用Floorservice镶木地板清洁剂湿洗。
(请遵循维护指南！)
如果地板表面有磨损的痕迹，就应当彻底清洗，然后用Floorservice护理油来处理。特别注意必须在地板表面磨损到木层之前进行再处理，否则就必须对地板进行沙磨并随后再补平。
用量/产率
用量20-30 ml/m²。
工具的清洁
在工具干燥之前使用市售石油溶剂油进行清洁。
储存
储存于阴凉干燥处，并闭合容器。
容器
10升或30升铁皮制容器。
安全信息
在阻燃表面上浸湿或干燥吸满了Profiline硬质蜡油的布块 (有自燃的危险！)。然后随生活废物一起弃置。天然产品，勿令孩童接触。
由于天然原材料的使用，可能会有一种特有的典型气味！
弃置
容器应于擦净后弃置于回收中心。干燥后的产品残留可与生活废物一起弃置。
| Chinese to English: 血凝抑制试验-Hemagglutination Inhibition Test
Detailed field: Medical (general) | Source text - Chinese
受体破坏酶处理血清
目的是去除非特异性血凝抑制素。因为人和动物血清中存在非特异性血凝抑制素，它们是游离在血清中类似病毒受体的唾液酸残基，能与病毒血凝素分子上的受体结合，会竞争抑制病毒与红血球的结合，因而造成假阳性，因此HI试验必须用受体破坏酶处理血清。具体操作如下：
1、3体积的RDE，1体积的血清（0.3ml RDE : 0.1ml血清）混合。
2、37℃水浴过夜。
3、56℃ 30min失活。
4、加入6体积的PBS或生理盐水混合，使血清稀释为1:10备用。或者按4:1处理后，倍比稀释为1:10备用。
(二)血凝素抑制(HI)试验操作过程
1、加PBS或生理盐水25μl于96孔板的第B行至H行的每一孔。
2、加1:10稀释的经受体破坏酶处理过的标准血清50μl于A行的每一孔。
3、用多通道移液器从A行各孔取25μl血清，倍比稀释至H排各孔，弃去25μl。
4、25μl被检病毒的4个血凝单位抗原加至各孔，混匀，室温静置15-30min，
5、然后加50μl的红血球（0.5%鸡红细胞或0.75%豚鼠红细胞），
6、室温静置30-60min（鸡血球30min；豚鼠血球60min）后观察结果。
结果判定
血凝被完全抑制的血清最大稀释度的倒数为血凝抑制试验的终点，该孔稀释度即为HI试验的效价。
---- 来源: 生命经纬 > 生命科学 > 微生物学 | Translation - English
Receptor-destroying enzyme (RDE) treatment of serum samples
The objective is to eliminate non-specific hemagglutination inhibitors. Serum samples used for HI tests have to be treated with RDE first, because there are non-specific hemagglutination inhibitors in humane and animal serum. Non-specific hemagglutinators exist as free virus receptor-like sialic acid group and can bind to receptors on virus hemagglutinin, thus competing with binding of red blood cells to the virus and producing false positive results. The procedure is as following:
1. Mix 3 volume of RDE with 1 volume of serum (0.3ml RDE : 0.1ml serum).
2. Incubate at 37'C water bath overnight.
3. Heat-inactivate by incubating at 56'C for 30min.
4. Add 6 volumes of PBS or saline and mix-- thus dilute the serum 1:10 for use in the test. Or the serum can be treated at 4:1 ratio, and then serial dilute to 1:10 for use in the test.
II. Hemagglutination-inhibition (HI) test protocol
1. Load 25µl/well PBS to wells in row B to row H of a 96-well-plate.
2. Add 50µl/well 1:10 diluted receptor-destroying enzyme treated standard serum to wells in row A.
3. Take 25µl/well of serum from row A and transfer to next row using multichannel pipette. Serial dilute by transfering 25µl to next row until row H. Discard the final 25µl from row H.
4. Add 4 HA unit of Ag for the testing virus in 25µl to each well. Mix well. Incubate at room temperature for 15-30 min.
5. Add 50µl red blood cells (0.5% chicken red blood cells or 0.75% guinea pig red blood cells).
6. Incubate at room temperature for 30-60min (30min for chicken red blood cells; 60min for guinea pig red blood cells), then read plate for results.
Measurement Evaluation
The reciprocal of highest serum dilution with which the hemagglutination is totally inhibited is the end point of the HI test. The dilution factor of that well is the titer of the HI test. |
More Less | | Chemistry, Drug, Finance, General, health/medicine, Literary | | Years of translation experience: 3. Registered at ProZ.com: Jan 2007. | | N/A | Chinese to English (Ph.D. in Comparative Pathology)
English to Chinese (PhD in Comparative Pathology)
| | ATA | | Highly Specialized Chinese-English Translations | | Adobe Acrobat, Adobe Photoshop, Dreamweaver, Frontpage, Microsoft Excel, Microsoft Word, Powerpoint, SDL TRADOS, SDLX | | CV will be submitted upon request | | About me
1) In an email titled "my compliments to you on your excellent work" from a US agency regarding a Chinese>English translation of research papers (font styles- underline, bold, and italic- shown as appeared in the email text):
"I have spent the last couple of days reviewing the translations from you, ****, and another translator we had working on this project. I must say, your work is absolutely excellent." "... your layout of the document, matching the original, is top notch and very helpful to me."
"...... So, I just wanted to relay to you how grateful I am for your hard work.
I will definitely work with you again in the future and if you ever need a reference, I will be happy to provide one for you."
2) From an Argentine agency, regarding an English>Chinese biochemistry translation:
"It's good to work with people like you that always meet deadlines and cares about the accuracy of each part of their job."
3) Forwarded comments from an MD reviewer, regarding a Chinese>English medical translation:
"Altogether, the translator did an excellent job!"
4) From a US agency, regarding a Chinese>English translation of clinical trial results:
"Thanks a lot for doing such a great job, as usual."
5) From a French agency, regarding a Chinese>English proofreading job:
"See comments from client
Wanted to pass that on where it belongs
Praise happens rarely enough
Hope it makes your day"
6) From a UK agency, regarding a Chinese>English pharmaceutical patent translation:
"Thank you very much for a speedy delivery. We appreciate your hard work ...
Well done!"
7) From a UK agency regarding a long-term, still ongoing Chinese>English medical translation project:
"As one of the most reliable and valued translators working on the xxxx account, ..."
8) From a US agency regarding an English> Chinese survey translation and tabulation of survey responses:
"Thanks so much for coming through for us. It is GREATLY appreciated."
"You really went the extra mile for us!"
9) From a US agency regarding an Chinese>English medical proofreading job:
"Its hard to find qualified translators who can edit and xxxx (another PM in the same company) spoke highly of you"
Chinese
Speak standard Mandarin. Read both simplified and traditional Chinese. Write simplified Chinese. Can input traditional Chinese characters too.
English
American English.
Medical science major
Educated in China and in United States. Extensive scientific writing experience in both Chinese and English.
Trained in medical science yet having an unsurpassed passion for languages and literature, I am proud to combine professional knowledge and language skills into high quality translations.
I specialize in general medicine, pharmaceutics, infectious disease, cardiology, virology, immunology, pathology, pediatrics, medical research, drug development and life science, et. al. My translations are precise and faithful to the source texts and versatile in style. They stand up to the scrutiny of medical experts in both languages I work with.
Being a freelancer, I understand the importance of keeping every customer that already found me, and I keep my customers by quality. In addition, I take on a project only when I am sure that I can finish it on time, and I always double check all the specialized terms before delivery. I love languages and spare no effort in perfecting a translation job.
E-mail me!
在中国/美国接受多年医学教育，并一直从事医学研究，提供优质医学汉英/英汉翻译服务。
擅长中、英文科技写作。文风灵活多变翻译精准，作品经得起中英文医学专家的严格审察。
专业范围：医学、药学、内科、外科、病理（科）、传染病（科）、心血管疾病（科）、小儿科、病毒学、免疫学、医学研究、药物研究、生命科学。
尊重客户，严格守时，以质取胜。坚持在交工前重复检察确认所有的专业词汇。热爱语言文字，不惜时惜力，让翻译作品更精更准。
邮件联系我
| This user has earned KudoZ points by helping other translators with PRO-level terms. Click point total(s) to see term translations provided.
|
Keywords: Chinese-English/English-Chinese translation/interpretation, science, technology, medicine, medical/pharmaceutical patent, clinical trial, informed consent form, instruction, research paper, survey, experiment, evaluation, medical history, health care, health insurance, medical instruments, public health, nurse, emergency care, traditional Chinese medicine, epidemiology, hospital, lab tests, blood transfusion, anesthesia, radiology, cardiology, medical science, biology, biochemistry, pharmaceutical, pharmaceutical kinetics, toxicity, medical instrument, medical procedure, medical history questionnaire, pathology, infectious disease, immunology, virology, microbiology, immunopathology, molecular biology, influenza, tuberculosis, hepatitis, SARS, quarantine, coronavirus, surgery, pediatric, vaccine, vaccination, inoculation, AIDS, HIV, immunodeficiency, genetics, antibody, neutralizing antibody, cellular immunity, heamagglutin, apoptosis, antiviral, drug screening, 英汉/汉英翻译, 笔译/口译, 医学翻译, 科学, 科技, 医学, 说明书, 临床试验, 知情同意书, 公函, 药学, 试验, 评估, 健康, 公众卫生, 医疗保险, 中医, 流行病学, 医院, 病历, 护士, 化验, 输血, 急诊, 麻醉, 放射科, 心血管科, 生物学, 生物科学, 生命科学, 生物化学, 药学, 医药动力学, 毒性, 药物毒理, 分子生物学, 外科, 医疗器械, 病史调查, 问卷, 病理学, 传染病, 免疫学, 病毒学, 微生物学, 免疫病理学, 流感, 结核, 肝炎, 非典型性肺炎, 冠状病毒, 隔离, 手术, 儿科, 疫苗, 接种, 爱滋病, 后天性免疫缺陷性病毒, 人体免疫缺陷性病毒, 免疫缺陷, 抗体, 中和抗体, 细胞免疫, 细胞凋零, 血凝, 抗病毒, 药物筛选, 静脉滴注
Profile last updated
Jan 13 |
The translation workplace 
Translation industry wiki
